Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Mott, David

doi:10.1007/s40271-018-0305-9

Cited by 48 publications

(52 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants would integrate the results of PPS in a separate section of the assessment report or in the discussion. According to Mott [26], PP can be incorporated into economic evaluations by using them within the calculation of the QALY. NICE recently stated that they do not want to use PP to value health states in CEA as this valuation needs to reflect societal values, rather than patient values, but that PP "could potentially provide additional support that would enable decision makers to make more informed recommendations in cases where the clinical trial data in isolation might not provide a clear demonstration on precisely what the value proposition is for patients" [38,39].…”

Section: Hta Stagementioning

confidence: 99%

See 1 more Smart Citation

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

Overbeeke

Forrester

Simoens

et al. 2020

Patient

View full text Add to dashboard Cite

Objective Patient preferences can be informative for health technology assessment (HTA) and payer decision making. However, applications may be different per country. The aim of this study therefore was to investigate HTA representatives' opinions on whether and how to incorporate patient preferences in HTA in their respective countries. Methods Three country-specific focus groups were conducted with three to seven HTA representatives from Germany, Belgium, and Canada. A predefined focus group guide was used that covered topics relating to how patient preferences can be used in HTA, namely HTA stage, weight, impact, and quality, as well as a case example of gene therapy. Transcripts were analyzed using NVivo 12 following thematic analysis. Results Across all HTA bodies, an interest in the use of patient preferences was observed for scientific advice and value assessments, but not through incorporation in quality-adjusted life-years and multi-criteria decision analysis. HTA representatives found it difficult to determine the weight patient preferences may receive in decision making, but thought it could have an impact on payer decision making if the study is of acceptable quality. Conclusions In the near future it may be impossible to achieve structural integration of patient preferences with other evidence in HTA (e.g., in cost-effectiveness analysis), but HTA bodies are willing to incorporate patient preferences in other HTA sections as supportive evidence. To allow for that use, future work should focus on meeting HTA and payer needs when conducting patient preference studies and on education of HTA and payer representatives regarding these studies.

show abstract

Section: Hta Stagementioning

confidence: 99%

“…Actual application of PP in HTA remains limited and not systematic [22,26]. Huls et al [27] identified issues of conceptual, normative, structural, procedural, or methodological nature currently blocking the integration of PP in HTA.…”

Section: Introductionmentioning

confidence: 99%

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

Overbeeke

Forrester

Simoens

et al. 2020

Patient

View full text Add to dashboard Cite

show abstract

“…However, by their very nature, DCEs are often bespoke, whereas decision-makers often value standardization in their decision-making procedures. Therefore, using these measures might be a challenge for those performing and using HTAs [19]. However, it may be possible to standardize the attributes and levels used in DCEs in the healthcare field.…”

Section: Incorporating Patient Preferences In Assessments Of Health Tmentioning

confidence: 99%

Should health technology assessment be more patient centric? If so, how?

2020

View full text Add to dashboard Cite

“…It should also be noted that whilst we elicited preferences from experienced patients (i.e. those who had received antibiotics recently), funding decisions are often made based on general population preferences [37,38]. The advantage is that our sample will be more informed than the general population, but the disadvantage is that the results may not be representative of the general populations of the study countries.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance

Mott

Hampson

Llewelyn

et al. 2019

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

Background Novel diagnostics are needed to manage antimicrobial resistance (AMR). Patient preferences are important in determining whether diagnostic tests are successful in practice, but there are few data describing the test attributes which matter most to patients. We elicited patients’ preferences for attributes of diagnostic tests that could be used to reduce unnecessary antibiotic use in primary care across seven European countries. Methods We used an online stated preference survey, including a discrete choice experiment (DCE). The DCE explored how patients make trade-offs between three key attributes of diagnostic tests: the speed that results were available, confidence in the test results, and how convenient it is to take the test. Individuals were eligible to complete the survey if they had taken antibiotics within the last 2 years and were resident in Germany, Italy, Spain, France, Greece, the Netherlands or the United Kingdom (UK). Results In total, 988 respondents completed the survey. The DCE responses illustrated that speed was the least important attribute in most countries. Responses from Germany and the Netherlands indicated that confidence was most important in these countries. Responses from the UK, France, Spain and Italy showed convenience as the most important attribute in these countries. Two attributes, confidence and convenience, were jointly favoured by respondents in Greece. Conclusion Patients in different European countries do not have the same preferences for the attributes of diagnostic tests to manage AMR in primary care. Failure to account for such differences during test development could reduce test uptake, result in continued overuse of antibiotics, and hamper marketisation.

show abstract

Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Cited by 48 publications

References 40 publications

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

Should health technology assessment be more patient centric? If so, how?

A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance

Contact Info

Product

Resources

About